Journal: Journal of Clinical Medicine

Article Title: Mesoporous Silica-Based Nanoparticles as Non-Viral Gene Delivery Platform for Treating Retinitis Pigmentosa

doi: 10.3390/jcm11082170

Figure Lengend Snippet: Transfection efficacy of PRPF31 gene using the nanoparticle delivery system PRPF31 -GFP/N-MSiNPs in a human cell line. Panels ( a – g ), immunofluorescence images of HEK-293 cells transfected with N-MSiNPs loaded with the PRPF31 -GFP plasmid. GFP fluorescent signal ( a , d ), in green; anti-PRPF31 fluorescent signal ( e ), in red. Cell nuclei were stained with DAPI ( b , f ), in blue. Merged images of the different channels are shown in ( c , g ). ( h ) WB of HEK-293 transfected cells showing the expression levels of the PRPF31 transgene fused to GFP. Protein extracts of HEK-293 treated with only Lipofectamine (negative control), in lane 1; from cells transfected with PRPF31 -GFP using Lipofectamine, in lane 2; from cells incubated with empty N-MSiNPs, in lane 3; and from cells transfected with N-MSiNPs loaded with PRPF31 -GFP, in lane 4. WBs were performed with anti-GFP (upper panel) and anti-PRPF31 (central panel) antibodies. GAPDH was used as a loading control (bottom panel). The (*) in the upper and central panels marks the expected molecular weight (80 kDa) of the PRPF31-GFP fused protein visualized by anti-GFP and ant-PRPF31 antibodies. The (#) in the central panel marks the expected molecular weight (55 kDa) of the endogenous PRPF31 protein. Scale bars represent 25 and 50 µm.

Article Snippet: Incubation with primary antibodies anti-PRPF31 (1:100; OriGene Technologies Inc., TA302582) and anti-GFP (1:200; Cell signaling 2956) was performed for 1 h at room temperature.

Techniques: Transfection, Immunofluorescence, Plasmid Preparation, Staining, Expressing, Negative Control, Incubation, Molecular Weight

Journal: Journal of Clinical Medicine

Article Title: Mesoporous Silica-Based Nanoparticles as Non-Viral Gene Delivery Platform for Treating Retinitis Pigmentosa

doi: 10.3390/jcm11082170

Figure Lengend Snippet: Fundus images and the retinal section of PRPF31 -GFP/N-MSiNP subretinally injected mice. ( a ) Fundus image. ( b ) Fluorescence fundus. ( c ) Detail of the injection site showing GFP fluorescent dots. Immunostaining of retinal sections for GFP ( d ), in green; PRPF31 ( e ), in red. Nuclei stained with DAPI ( f ), in blue. ( g ) Merged images of the different channels. GFP and PRPF31 signal co-localized mainly in RPE cells. RPE = retinal pigment epithelium, ONL = outer nuclear layer, INL = inner nuclear layer, GCL = ganglion cell layer. Scale bar represents 50 µm.

Article Snippet: Incubation with primary antibodies anti-PRPF31 (1:100; OriGene Technologies Inc., TA302582) and anti-GFP (1:200; Cell signaling 2956) was performed for 1 h at room temperature.

Techniques: Injection, Fluorescence, Immunostaining, Staining

Journal: Nature Communications

Article Title: PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

doi: 10.1038/ncomms7692

Figure Lengend Snippet: ( a ) CPT1A mRNA was analysed by real-time quantitative PCR and relative expression of mRNA of each time point and culture condition over the levels expressed in unstimulated cells (defined as 1) is shown (* P <0.05, T CC+PD1 versus T CC , Student’s t -test; ♦ P <0.05, T CC+PD1 versus UT and T CC versus UT, analysis of variance (ANOVA); n =3 experiments). ( b ) CD4 + primary human T cells were cultured under the indicated conditions. Cell lysates were prepared at the indicated time points and expression of CPT1A and β-actin were assessed by SDS–PAGE and immunoblot. Results are representative of three experiments. ( c ) Fatty acid β-oxidation rate after culture under the indicated conditions for various time intervals was examined. Values of T CC and T CC+PD1 cells were compared with unstimulated (UT) cells ( ♦ P <0.05, ANOVA; n =3) and values of T CC+PD1 were compared with T CC cells (* P <0.05, Student’s t -test; n =3).

Article Snippet: The anti-FASN (#3189) was from Cell Signaling Technologies, Danvers, MA, and the anti-CPT1A (#TA303144) antibody was from OriGene Technologies Inc., Rockville, MD.

Techniques: Real-time Polymerase Chain Reaction, Expressing, Cell Culture, SDS Page, Western Blot

Journal: Nature Communications

Article Title: PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

doi: 10.1038/ncomms7692

Figure Lengend Snippet: ( a ) CD4 + primary human T cells were cultured with tosyl-activated magnetic beads conjugated with aCD3/aCD28/IgG (T CC ) in the presence of either LY294002 (LY, 10 μM), UO126 (UO, 10 μM) or their combination. Cell lysates were prepared at the indicated time points and expression of CPT1A and β-actin was assessed by SDS–PAGE and immunoblot. Results are representative of three experiments. ( b – d ) In parallel experiments, rate of fatty acid β-oxidation was examined. Values of T CC +inhibitor cultures were compared with T CC (* P <0.05, Student’s t -test; n =3) and values of T CC and T CC +inhibitor cultures were compared with unstimulated (UT) ( ♦ P <0.05, analysis of variance (ANOVA); n =3). ( e ) At 72 h of culture under the indicated conditions, spare respiratory capacity (SRC) was determined. Values of T CC and T CC +inhibitor cells were compared with unstimulated (UT) cells ( ♦ P <0.05, ANOVA; n =3) and values in T CC +inhibitor cells were compared with T CC (* P <0.05, Student’s t -test; n =3). ( f ) T cells were cultured with tosyl-activated magnetic beads conjugated with aCD3/aCD28/PD-L1-Ig or with tosylatcivated magnetic beads conjugated with aCD3/aCD28/IgG in the presence of either LY294002 (LY, 10 μM), UO126 (UO, 10 μM) or their combination. Cell lysates were prepared at the indicated time points and expression of ATGL and β-actin was assessed by SDS–PAGE and immunoblot.

Article Snippet: The anti-FASN (#3189) was from Cell Signaling Technologies, Danvers, MA, and the anti-CPT1A (#TA303144) antibody was from OriGene Technologies Inc., Rockville, MD.

Techniques: Cell Culture, Magnetic Beads, Expressing, SDS Page, Western Blot

Journal: Nature Communications

Article Title: PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

doi: 10.1038/ncomms7692

Figure Lengend Snippet: CD4 + primary human T cells were either left unstimulated (UT) or were incubated with magnetic beads conjugated with αCD3/αCD28/IgG (T cells co-stimulated (T CC )) or magnetic beads conjugated with αCD3/αCD28/αCTLA-4 mAbs (T cells co-stimulated+ CTLA-4 (T CC+CTLA4 )). ( a ) Expression of Glut1 after culture under the indicated conditions and time intervals was examined by flow cytometry. Results are representative of three experiments. ( b – f ) mRNA for HK2, SNAT1, SNAT2, CPT1A and ATGL was analysed by real-time quantitative PCR and relative expression of mRNA of each time point and culture condition over the levels expressed in unstimulated cells (defined as 1) is shown. ( g ) Fatty acid β-oxidation rate after culture under the indicated conditions for various time intervals was examined. ( h , i ) Analysis of lactate ( h ) and 3-hyroxybutyrate ( i ), end metabolites of glycolysis and fatty acid β-oxidation, respectively, was performed in culture supernatants. (For the studies shown in all panels: * P <0.05, T CC+CTLA4 versus T CC , Student’s t -test; ♦ P <0.05, T CC versus UT and T CC+CTLA4 versus UT, analysis of variance; n =3 experiments).

Article Snippet: The anti-FASN (#3189) was from Cell Signaling Technologies, Danvers, MA, and the anti-CPT1A (#TA303144) antibody was from OriGene Technologies Inc., Rockville, MD.

Techniques: Incubation, Magnetic Beads, Expressing, Flow Cytometry, Real-time Polymerase Chain Reaction

Journal: Nature Communications

Article Title: PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

doi: 10.1038/ncomms7692

Figure Lengend Snippet: CD4 + human T cells were pre-activated with anti-CD3-and-anti-CD28 mAbs for 4 h or for 24 h and subsequently were collected, were left to rest for 3 h and re-cultured with tosyl-activated magnetic beads conjugated with αCD3/αCD28/PD-L1-Ig (Tpr4hr→PD-1 and Tpr24hr→PD-1). In the same experiment CD4 + T cells without pre-activation were stimulated with tosyl-activated magnetic beads conjugated with αCD3/αCD28/IgG (T CC ) and used as positive control for optimal stimulation without PD-1. ( a ) Expression of Glut1 after culture under the indicated conditions and time intervals was examined by flow cytometry. ( b , c ) mRNA for HK2 and CPT1A was analysed by real-time quantitative PCR and relative expression of mRNA of each time point and culture condition over the levels expressed in unstimulated cells (defined as 1) is shown. ( d ) Fatty acid β-oxidation rate after culture under the indicated conditions for various time intervals was examined. ( e , f ) Analysis of lactate ( e ) and 3-hydroxybutyrate ( f ), end metabolites of glycolysis and fatty acid β-oxidation, respectively, was performed in culture supernatants (for the studies shown in all panels: * P <0.05, Tpr4hr→PD-1 versus T CC or Tpr4hr→PD-1 versus T CC , Student’s t -test; ♦ P <0.05, T CC versus UT, Tpr4hr→PD-1 versus UT and Tpr4hr→PD-1 versus UT, analysis of variance; n =3 experiments).

Article Snippet: The anti-FASN (#3189) was from Cell Signaling Technologies, Danvers, MA, and the anti-CPT1A (#TA303144) antibody was from OriGene Technologies Inc., Rockville, MD.

Techniques: Cell Culture, Magnetic Beads, Activation Assay, Positive Control, Expressing, Flow Cytometry, Real-time Polymerase Chain Reaction

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: Representative images of maximum intensity projections (left) and optical sections (right) from mesentery collecting vessels of a 4 week old C57Bl6 mouse immunostained with VEGFR3 (white), FOXC1 (red), and FOXC2 (green). Purple arrowheads denote the position of valve leaflet free-edges. Yellow arrowheads denote FOXC1 HIGH /FOXC2 HIGH LECs located near the leaflet free-edge. Blue arrowheads denote FOXC2-positive LECs in valve leaflets with only weakly expressed FOXC1. Dashed blue lines on the single-channel images outline the vessel borders. Scale bars are 50 μm.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques:

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: qPCR analysis was performed on RNA extracted from CD31+ cardiac cells of P6 EC- Foxc1 -KO ( a ), EC- Foxc2 -KO ( b ), and EC- Foxc1; Foxc2 -DKO ( c ) individuals and littermate controls. Data are shown as mean relative expression (± SD) normalized to WT littermate controls and analyzed using Student’s t-test. N = 11 for Foxc1 Control and N = 12 for EC- Foxc1 -KO individuals, N = 14 for Foxc2 Control and N = 14 for EC- Foxc2 -KO individuals, N = 12 for Foxc1; Foxc2 Control and N = 11 for EC- Foxc1; Foxc2 -DKO individuals. *** denotes p<0.001. NS denotes no significance. ( d – i ) Representative images of FOXC1, FOXC2, and VEGFR-3 immunostained lymphatic collecting vessels from P6 littermate control ( d, f, h ) and EC- Foxc1 -KO ( e ), EC- Foxc2 -KO ( g ), and EC- Foxc1; Foxc2 -DKO ( i ) individuals. a, arterioles covered by FOXC1-positive smooth muscle cells. Scale bars are 25 µm.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Expressing

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a, b, g, h, m, n ) Representative images of PROX1 and CD31 immunostained lymphatic collecting vessels in P6 littermate control ( a, g, m ) and EC- Foxc1 -KO ( b ), EC- Foxc2 -KO ( h ), and EC- Foxc1; Foxc2 -DKO ( n ) individuals. White arrowheads denote PROX1-high valves. Scale bars are 500 μm. (c – f, i – l) Representative images of mature and immature lymphatic valves immunostained with PROX1 and CD31 or α9-integrin and VE-Cadherin in P6 littermate control ( c, d, i, j ) and EC- Foxc1 -KO ( e, f ) or EC- Foxc2 -KO individuals ( k, l ). Pink inserts denote single channel α9-integrin (white) images. Blue arrowhead denotes VE-Caderhin-positive intraluminal valve leaflet with markedly reduced α9-integrin expression in l. Scale bars are 25 μm. ( o, p ) Appearance of chylous ascites in the peritoneal cavity of a P6 EC-Foxc1; Foxc2 -DKO mouse ( p ) compared to littermate control ( o ). Blue arrow heads indicate chylous effusion; scale bar equals 1 mm. (q – t) Representative images of PROX1 immunostained lymphatic collecting vessels in P6 littermate control ( q, s ) and EC- Foxc2 -KO ( r ) or EC- Foxc1; Foxc2 -DKO ( t ) individuals show degeneration of lymphatic valves in Foxc2 mutants and regression of collecting vessels into a primitive lymphatic architecture in EC-specific Foxc1 and Foxc2 mutants. Pink arrowheads denote degenerating PROX1-high expressing valve regions. Yellow arrowheads highlight looping and interconnections between branches of collecting vessels. Scale bar is equal to 200 μm. ( u ) Quantification of total lymphatic valve number (identified by PROX1-high expression) in lymphatic collecting vessels of P6 Control and EC- Foxc1 -KO individuals. N = 7 for Control and N = 7 for EC- Foxc1 -KO individuals, four collecting vessels analyzed per individual. ( v ) Percentage of mature and immature lymphatic valves normalized to total valves counted in P6 Control and EC- Foxc1 -KO individuals. ( w ) Quantification of total lymphatic valve number in lymphatic collecting vessels of P6 Control and EC- Foxc2 -KO individuals. N = 9 for Control and N = 9 for EC- Foxc2 -KO individuals, four collecting vessels analyzed per individual. ( x ) Percentage of mature and immature lymphatic valves normalized to total valves counted in P6 Control and EC- Foxc2 -KO individuals. ( y ) Quantification of total lymphatic valve number in lymphatic collecting vessels of P6 Control and EC- Foxc1; Foxc2 -DKO individuals. N = 6 for Control and N = 6 for EC-Foxc1; Foxc2 -DKO individuals, four collecting vessels analyzed per control individual and all lymphatic collecting vessels assessed per mutant individual. Data are presented as mean (± SD) and analyzed using Student’s t-test. NS denotes no significance. ** denotes p<0.01. *** denotes p<0.001.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Expressing, Mutagenesis

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a, b ) Representative images of PROX1 and CD31 immunostained lymphatic collecting vessels in P6 Control ( a ) and LEC- Foxc1 -KO ( b ) individuals administered 100 μg of Tamoxifen from P1-5. Scale bars are 500 μm. ( c, d ) Representative images of PROX1 and FOXC1 immunostained lymphatic collecting vessels in P6 Control ( c ) and LEC- Foxc1 -KO ( d ) individuals administered 100 μg of Tamoxifen from P1-5. Scale bars are 20 μm. ( e ) Quantification of total lymphatic valve number in lymphatic collecting vessels of P6 Control and LEC- Foxc1 -KO individuals. N = 7 for Control and N = 8 for LEC- Foxc1 -KO individuals, four collecting vessels analyzed per individual. ( f ) Percentage of mature and immature lymphatic valves normalized to total valves counted in P6 Control and LEC- Foxc1 -KO individuals. Data are presented as mean (± SD) and analyzed using Student’s t-test. *** denotes p<0.001. NS denotes no significance.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques:

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: Representative, low and high-power images of P6 mesenteries immunostained with antibodies targeted towards α9-integrin and VE-Cadherin in Foxc2 Control ( a, e ), EC- Foxc2 -KO ( b, f ), Foxc1; Foxc2 Control ( c, g ), and EC- Foxc1; Foxc2 -DKO ( d, h ) individuals respectively. Yellow arrowheads highlight α9-integrin- positive lymphatic valves. Red arrowheads highlight α9-integrin- positive regressing lymphatic valves in Foxc2 mutants. Blue arrowheads denote lymphatic collecting vessels absent of α9-integrin positive valve expression in compound Foxc1; Foxc2 mutants. Scale bars are 200 µm in panels a – d and 25 μm in panels e – h.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Expressing

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a – d ) Representative images of lymphatic collecting vessels immunostained with antibodies targeted to PROX1 and VE-Cadherin in a P6 EC- Foxc2 -KO ( b ) and littermate control ( a ), and EC- Foxc1; Foxc2 -DKO ( d ) and littermate control ( c ) individuals respectively. Scale bars are 25 μm. ( e – h ) Representative images of VE-Cadherin immunostaining in magnified fields denoted by boxed regions in ( a – d ) show discontinuous cell-cell junctions (blue arrowheads) observed in both EC- Foxc2 -KO and EC- Foxc1; Foxc2 -DKO mice and the presence of overlapping cell junctions (pink arrowheads) upon combined inactivation of Foxc1 and Foxc2 ( h ). ( i, j ) Representative images of PROX1 and cleaved caspase-3 antibody immunostained lymphatic collecting vessels from P6 littermate control ( i ), and EC- Foxc1; Foxc2 -DKO ( j ) individuals. Boxed regions denote corresponding magnified z-section images from confocal maximum intensity projections represented in i ) and j ). Scale bars are 100 μm. ( k ) Quantitative analysis of the percentage of PROX1/cleaved caspase 3-positive LECs in 20X high-powered fields from mesentery collecting vessels of P6 Foxc1; Foxc2 Control and EC- Foxc1; Foxc2 -DKO individuals. N = 27 fields from six individuals for Foxc1; Foxc2 Control and N = 34 fields from seven individuals for EC- Foxc1; Foxc2 -DKO individuals. Data are presented as mean (± SD) and analyzed using Student’s t-test. **** denotes p<0.0001.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Immunostaining

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a ) Representative images of cultured LECs under static, OSS, or LSS show increased expression of FOXC1 when subjected to 24 hr to LSS, whereas FOXC2 is induced by both OSS and LSS. Immunostaining for β-catenin (red), FOXC1 (white, top panels), and FOXC2 (white, bottom panels). Nuclei are outlined with dashed blue lines. Arrowheads denote cells with strong nuclear expression of FOXC1 or FOXC2. Scale bars are 10 μm. ( b ) Corresponding quantification of FOXC1 or FOXC2 nuclear intensity per cell (100–200 cells were quantified per condition). Data are presented as violin plots with median values indicated by solid lines and are representative of 3 independent experiments. P-values were obtained using mixed-effects analysis. ***p<0.001, ****p<0.0001 to Static FOXC1 and ▪▪▪▪ p<0.0001 to Static FOXC2 . ( c ) Scheme summarizing the observed regulation of FOXC1 and FOXC2 by flow-mediated shear stress: cells under OSS have high levels of FOXC2, whereas cells under LSS have high levels of both FOXC1 and FOXC2.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Cell Culture, Expressing, Immunostaining

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a–c ) Relative FOXC1 and FOXC2 nuclear intensity was quantified per each cell and a linear regression analysis was applied with FOXC1 intensity on the x-axis and FOXC2 intensity on the y-axis for static ( a ), OSS ( b ), and LSS ( c ) assuming interaction with 0 for both axes. The correlation coefficient (R 2 ) is indicated on each graph in association with the linear regression and shows absence of correlation. ( d–e ) Representative images of confluent LECs 2 days after transfection with control siRNA (upper) or two different target-specific siRNA (middle and lower) showing efficient knockdown in each case. Cells were immunostained for β-catenin (white) and FOXC2 (red) in ( d ) or FOXC1 (green) in ( e ). Scale bars are 30 µm.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Transfection

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a ) Representative images of Control and FOXC1-KD LECs cultured under static, OSS, or LSS show reduced viability and higher number of contractile stress fibers (cyan arrowhead). Immunostaining for VE-Cadherin (red), F-actin (green), p-MLC2 (white), and DNA (blue). Pink arrowheads denote areas devoid of cells in the endothelial monolayer. Pink inserts denote single-channel p-MLC2 (white) images. Scale bars are 30 μm. ( b, c ) Representative images of Control, FOXC1 -KD, FOXC2 -KD, and combined FOXC1 -KD/ FOXC2 -KD LECs show higher number of contractile stress fibers (b, pink arrowhead) and focal adhesions (c, cyan arrowhead) upon FOXC1 knockdown. In comparison, FOXC2 knockdown rather induced focal adherens junctions (c, pink arrowhead). ( b ) Immunostaining for F-actin (red), p-MLC2 (green), and DNA (blue). Images on the right show a mask applied to visualize only double F-actin + /p-MLC2 + (white) stress fibers. Scale bars are 30 μm. ( c ) Immunostaining for F-actin (red), vinculin (green), and DNA (blue). Images on the right show a mask applied to visualize only double F-actin + /vinculin + (white) adhesion sites. Scale bars are 30 μm.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Cell Culture, Immunostaining

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a ) Representative images of Control, FOXC1 -KD, FOXC2 -KD, and combined FOXC1 -KD/ FOXC2 -KD LECs show overlapping junctions (pink arrowhead) upon FOXC1 knockdown but disrupted junctions (cyan arrowhead) upon FOXC2 knockdown. Immunostaining for VE-Cadherin (white) and FOXC1 (red). Images on the right show a 4x zoom of the area delineated by the pink box. Scale bars are 50 μm. ( b ) Representative images of Control, FOXC1 -KD, FOXC2 -KD, and combined FOXC1 -KD/ FOXC2 -KD LECs show overlapping junctions (pink arrowhead) upon FOXC1 knockdown but disrupted junctions (cyan arrowhead) upon combined FOXC1 and FOXC2 knockdown. Immunostaining for β-catenin (white) and DNA (blue). Images on the right show immunostaining for F-actin (red), DNA (blue) and a mask applied to visualize only double F-actin + /paxillin + (green) adhesion sites. Yellow arrowheads denote increased focal adhesions. Red arrowheads denote increased focal adherens junctions at the cell cortex. Scale bars are 30 μm.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Immunostaining

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a ) Reduced expression of Prickle1 , Arhgap21 , and Arhgap23 in Foxc1/c2 -compound mutant LECs isolated from the dorsal skin at E15.5. Graph shows RPKM values from RNA-seq analysis. *** denotes p<0.001. ( b, c ) Putative FOX-binding sites in regions of the human PRICKLE1 locus as viewed on the UCSC genome browser ( http://genome.ucsc.edu ; ). Vertical lines on the ‘FOX sites’ track indicate putative FOX binding sites predicted using HOMER (see methods). Red boxes indicate evolutionary conserved regions (ECRs) containing FOX-binding sites between human and mouse genomes that are conserved and aligned. ( d ) ChIP showing specific binding of FOXC1 and FOXC2 to the consensus FOX-binding sites within ECRs 1, 2, 3, 4, 5, and six in PRICKLE1 in HDLECs. ( e–j ) ChIP assays were performed using antibodies against Foxc1, Foxc2, and normal goat IgG. The binding of FOXCs to candidate ECRs identified in b and c in the PRICKLE1 locus was determined with regular PCR and expressed as relative folds of input whose band intensity was normalized to 1. Data are presented as a scatter plot with median indicated in red. * denotes p<0.05, ** denotes p<0.01 as determined by Mann-Whitney two-tailed test. ( k–p ) Representative images of lymphatic valve regions in mesenteric collecting vessels immunostained with antibodies targeted to Prickle1 and PROX1 in P7 Foxc1 Control ( k ), EC- Foxc1 -KO ( l ), Foxc2 Control ( m ), EC- Foxc2 -KO, ( n ) Foxc1; Foxc2 control and ( o ) EC- Foxc1; Foxc2 -DKO ( p ) mice show reduced Prickle1 expression in the valve leaflets and lymphangion of Foxc2 and compound Foxc1; Foxc2 mutants compared to littermate controls whereas Prickle1 is reduced primarily in leaflet-free-edge LECs, denoted by yellow asterisks, of Foxc1 mutants. Scale bars are 20 μm.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Expressing, Mutagenesis, Isolation, RNA Sequencing Assay, Binding Assay, MANN-WHITNEY, Two Tailed Test

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a, b ) Putative FOX-binding sites in regions of the human ARHGAP21 ( a ) and ARHGAP23 ( b ) loci as viewed on the UCSC genome browser ( http://genome.ucsc.edu ; ). Vertical lines on the ‘FOX sites’ track indicate putative FOX binding sites predicted using HOMER (see methods). Red boxes indicate ECRs containing FOX-binding sites between human and mouse genomes that are conserved and aligned. ( c, d ) ChIP showing specific binding of FOXC1 and FOXC2 to the consensus FOX-binding sites within ECRs in ARHGAP21 ( c ) and ARHGAP23 ( d ) in HDLECs. ( e–h ) ChIP assays were performed using antibodies against Foxc1, Foxc2, and normal goat IgG. The binding of FOXCs to candidate ECRs in the ARHGAP21 ( e–g ) and ARHGAP23 ( h ) loci was determined with regular PCR and expressed as relative folds of input whose band intensity was normalized to 1. Data are presented as a scatter plot with median indicated in red. * denotes p<0.05, ** denotes p<0.01 as determined by Mann-Whitney two-tailed test.( i ) Lack of FOX-binding sites in a region of the human ICAM1 locus as viewed on the UCSC genome browser. Red arrowheads denote a ChIP negative control PCR amplified region of the ICAM1 promoter, which was predicted to not bind FOX transcription factors. ( j ) ChIP assays were performed from three replicates using antibodies against Foxc1, Foxc2, and normal goat IgG. PCR was performed using primers to a negative control region of the ICAM1 promoter ( i ). ( k ) Expression of RhoA, Rock1, Rock2, Arhgap5, Arhgap18, Arhgap19, Arhgap20, Arhgap29, and Arap3 in littermate Control and Foxc1/c2 -compound mutant LECs isolated from the dorsal skin at E15.5. Graph shows RPKM values from RNA-seq analysis. * denotes p<0.05, *** denotes p<0.001.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Binding Assay, MANN-WHITNEY, Two Tailed Test, Negative Control, Amplification, Expressing, Mutagenesis, Isolation, RNA Sequencing Assay

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a–f ) High magnification, representative images from two separate angles of three-dimensional reconstructions of PROX1 and Prickle1 immunostained collecting vessel generated from the same fields of P7 control individuals depicted in and as well as the P7 EC- Foxc1 -KO individual depicted in . ( g–i ) Representative images of a single z-slice generated from the three-dimensional reconstructions depicted in panels ( a–f ). Yellow asterisks denote LECs located at the leaflet-free-edge. Blue arrowheads denote Prickle1 expression in leaflet-free-edge LECs. Yellow arrowheads denote areas of the valve buttress, which anchors leaflets to the vessel wall, where Prickle1 is expressed. Scale bars equal 10 μm.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Generated, Expressing

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a ) Representative images of cultured LECs transfected with scramble control siRNA or FOXC1 siRNA and treated with vehicle control or Y-27632 (10 µM). Treatment with Y-27632 ROCK inhibitor shows rescue of cytoskeletal changes induced by FOXC1 inactivation. Immunostaining of F-actin (red), p-MLC2 (green), and DNA (blue). Pink inserts denote the single-channel p-MLC2 (white) images. Scale bars are 20 µm. ( b ) Quantification of relative F-actin (left) and p-MLC2 (right) area per Control (dark grey bars) and FOXC1 -KD (light grey bars) cells treated with vehicle Control (blue outline) or Y-27632 (red outline). ( c ) Representative images of Control and FOXC2-KD LECs cultured under static, OSS, or LSS, treated with vehicle Control or Y-27632 (10 µM). Treatment with Y-27632 ROCK inhibitor shows rescue of cytoskeletal changes induced by FOXC2 inactivation that are most prominent under OSS. Immunostaining for VE-Cadherin (red), F-actin (green), p-MLC2 (white), and DNA (blue). Pink inserts denote the single-channel p-MLC2 (white) images. Scale bars are 20 µm. ( d ) Quantification of relative F-actin (top) and p-MLC2 (bottom) area per Control (dark grey bars) and FOXC1 -KD (light grey bars) cells treated with vehicle Control (blue outline) or Y-27632 (red outline).

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Cell Culture, Transfection, Immunostaining

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a–h ) Representative images of lymphatic collecting vessels immunostained with PROX1 antibody in P7 littermate Control ( a ) and EC- Foxc2 -KO ( b ), littermate Control ( e ) and EC- Foxc1; Foxc2 -DKO ( f ) mice subcutaneously injected with DPBS vehicle or littermate Control ( c ) and EC- Foxc2 -KO ( d ), littermate Control ( g ) and EC- Foxc1; Foxc2 -DKO ( h ) mice subcutaneously injected with ROCK inhibitor Y-27632. Scale bars equal to 500 μm. ( i, j ) Quantification of total valve number ( i ) and percentage of mature valves ( j ) in littermate Control and EC- Foxc2 -KO mice administered DPBS or Y-27632. N = 6 for Control DPBS, N = 6 for EC- Foxc2 -KO DPBS, N = 9 for Control Y-27632, and N = 9 for EC- Foxc2 -KO Y-27632. ( k ) Quantification of total valve number in littermate Control and EC- Foxc1; Foxc2 -DKO mice administered DPBS or Y-27632. N = 5 for Control DPBS, N = 7 for EC- Foxc1; Foxc2 -DKO DPBS, N = 8 for Control Y-27632, and N = 9 for EC- Foxc1; Foxc2 -DKO Y-27632. P-values were obtained by One-way ANOVA with Tukey’s post test. Data are presented as mean (± SD). ** denotes p<0.01. *** denotes p<0.001. NS denotes no significance.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Injection

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a–h ) High-magnification, representative images of lymphatic collecting vessels immunostained with VE-Cadherin antibody in P7 littermate Control ( a ) and EC- Foxc2 -KO ( b ), littermate Control ( e ) and EC- Foxc1; Foxc2 -DKO ( f ) mice subcutaneously injected with DPBS vehicle or littermate Control ( c ) and EC- Foxc2 -KO ( d ), littermate Control ( g ) and EC- Foxc1; Foxc2 -DKO ( h ) mice subcutaneously injected with ROCK inhibitor Y-27632. Scale bars are 20 µm. Red, dashed boxes highlight magnified regions shown inset. Scale bars equal to 5 μm. Gaps in LEC junctions are visible in EC- Foxc2 -KO and EC- Foxc1; Foxc2 -DKO mice administered DPBS ( b, f ) whereas inhibition of ROCK with Y-27632 is able to restore linear junctions in part ( d, h ). Blue arrowheads denote discontinuous LEC VE-Cadherin junctions.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Injection, Inhibition

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: ( a ) Schematic representation of the targeting vector and targeted allele. The entire protein coding region of Foxc1 is replaced with that of Foxc2 . ACN, self-excision cassette including Cre driven by the testis-specific promoter. ( b ) Southern blot analysis to detect double-resistant ES cell colonies using 5’ and 3’ probes. ( c ) PCR genotyping of F1 heterozygotes to detect the Foxc1 c2 allele. ( d, e ) Representative images of lymphatic valves in mesenteric collecting vessels immunostained with antibodies targeted to FOXC1 and VEGFR-3 from P12 P6 Foxc1 +/+ ( d ) and Foxc1 c2/c2 ( e ) mice. Scale bars are 25 µm. (f – h) Representative images of lymphatic valves in mesenteric collecting vessels immunostained with antibodies targeted to FOXC1, FOXC2, and VE-Cadherin from P6 Foxc1 +/+ ( f ) , Foxc1 c2/+ ( g ), and Foxc1 c2/c2 mice ( h ). Scale bars are 50 μm. (i – k) Representative images of the mesenteric vasculature immunostained with antibodies targeted to PROX1 and CD31 in P6 Foxc1 +/+ ( i ) , Foxc1 c2/+ ( j ), and Foxc1 c2/c2 mice ( k ). Scale bars are 200 μm. (l – n) Representative images of P6 mesenteric vasculature from P6 Foxc1 +/+ ( l ) , Foxc1 c2/+ ( m ), and Foxc1 c2/c2 mice ( n ) immunostained with antibodies targeted to FOXC1, FOXC2, and VE-Cadherin show gradual loss of FOXC1 expression in the blood and lymphatic vasculature and smooth muscle cells and conversely the increase of FOXC2 expression in blood vasculature and smooth muscle. Scale bars are 200 μm. ( o ) Quantification of total lymphatic valve number in lymphatic collecting vessels of P6 Foxc1 +/+ , Foxc1 c2/+ , and Foxc1 c2/c2 individuals. N = 6 for Foxc1 +/+ , N = 8 for Foxc1 c2/+ , and N = 8 for Foxc1 c2/c2 individuals. ( p ) Percentage of mature and immature lymphatic valves normalized to total valves counted in P6 Foxc1 +/+ , Foxc1 c2/+ , and Foxc1 c2/c2 individuals. Data are presented as mean (± SD) and analyzed using Student’s t-test. NS denotes no significance.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Plasmid Preparation, Southern Blot, Expressing

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: Collecting vessels in the postnatal lymphatic vasculature are characterized by the presence of a high number of intraluminal bi-leaflet valves. These regions are exposed to disturbed flow in the valve sinuses (2) which strongly induces the expression of FOXC2. In contrast, the intraluminal side of valve leaflets is exposed to pulsatile laminar shear (1), which induces FOXC1 in addition to FOXC2. In the absence of FOXC1 and FOXC2, the cytoskeleton undergoes remodeling events in which actomyosin contractility is strongly induced with focal adhesion dynamics perturbed by loss of FOXC1 and intercellular junctions perturbed by loss of FOXC2, ultimately leading to valve degeneration.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Expressing

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: Expression of focal adhesion regulatory genes Actn1, Itgb3, Src, Tln1, Tln2, Tns1, Tns3, and Vcl in littermate Control and Foxc1/c2 -compound mutant LECs isolated from the dorsal skin at E15.5. Graph shows RPKM values from RNA-seq analysis. * denotes p<0.05, ** denotes p<0.01, and *** denotes p<0.001.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Expressing, Mutagenesis, Isolation, RNA Sequencing Assay

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: Antibodies and Dyes.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Transduction

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: Primers used for qPCR analysis.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques:

Journal: eLife

Article Title: Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation

doi: 10.7554/eLife.53814

Figure Lengend Snippet: List of siRNAs.

Article Snippet: The sheared chromatin was immunoprecipitated with dynabeads (Invitrogen, #10004D) conjugated with anti-FOXC2 antibody (Abcam, ab5060), anti-FOXC1 antibodies (Origene, TA302875 and Abcam, ab5079), or control IgG (Thermo Fisher Scientific, # 02–6202).

Techniques: Sequencing

Journal: Molecular Psychiatry

Article Title: Inhibition of colony stimulating factor 1 receptor corrects maternal inflammation-induced microglial and synaptic dysfunction and behavioral abnormalities

doi: 10.1038/s41380-020-0671-2

Figure Lengend Snippet: a Gene ontology (GO) biological processes pathway analysis shows that MIA microglia increase synaptogenic functions while repopulated microglia recover homeostatic functions. Left (red): Top significantly enriched GO biological process terms increased by MIA and decreased by repopulation. Right (purple): Top significantly enriched GO biological process terms decreased by MIA and increased by repopulation. These GO findings were verified using GORILLA. b IPA of genes with differential expression in microglia between MIA versus Saline (RNA-seq data). Pathway analysis reveals MIA-induced upregulation of neuritogenic gene expression, specifically in developmental stages, based on activation z -score. Red denotes pathway activated in E17 MIA microglia. c Genes in “neuritogenesis/formation of cellular protrusions” function. Hierarchal clustering of gene sets based on relative expression values; red: high relative expression, blue: low relative expression. Cluster 1 represents genes increased in adult MIA microglia but reduced in MIA + MG-REP including Ctnnd2, Ncam2, and Ntrk2 . Cluster 2 represents genes increased in immature MIA microglia including Ncam2, Ntn, Ptn and Wnt5a . Cluster3 represents genes decreased in immature MIA microglia including Plau. In situ hybridization (ISH) and immunofluorescence of E17 Saline or MIA offspring in the cortical plate region. d mRNA of cellular protrusion/ neuritogenic genes ( Ctnnd2, Ncam2, Ntn, Ptn, and Wnt5a ) were detected by florescent-labeled antisense cRNA probes (red) but not by scramble cRNA probe (not detected: N.D.), and the sections were immunostained for IBA1 (green) and DAPI (blue). e The number of IBA1 + cells expressing the cellular protrusion/neuritogenic genes were quantified in the cortical plate region. n = (4–5/2) male mice/ litters per molecule for Saline and MIA, n = 3 for scramble control probe. * p < 0.05, ** p < 0.01, ns denotes no significance, by unpaired Student t test. Graphs indicate mean ± s.e.m. ELISA verification of selected RNA-seq molecules: CTNND2 ( f ), NCAM2 ( g ), NTRK2 ( h ), NTN ( i) , PTN ( j ) and WNT5A ( k ) in acutely isolated microglia. MIA increases protein expression of cellular protrusion/neuriotgenic molecules in microglia that were normalized via repopulation. n = (6/4, 6/3, 5/3, 6/3) female mice/litters for P60 Saline + CTRL, MIA + CTRL, Saline + MG-REP and MIA + MG-REP. CTNND2: Prenatal treatment effect, F (1,19) = 157.1, p < 0.0001, Drug effect, F (1,19) = 262.7, p < 0.0001, Interaction effect, F (1,19) = 201, p < 0.0001, NCAM2: Prenatal treatment effect, F (1,19) = 23.76, p = 0.0001, Drug effect, F (1,19) = 26.29, p < 0.0001, Interaction effect, F (1,19) = 17.63, p = 0.0005, NTRK2: Prenatal treatment effect, F (1,18) = 13.99, p = 0.0015, Drug effect, F (1,18) = 12.45, p = 0.0024, Interaction effect, F (1,18) = 0.06203, p = 0.8061, NTN: Prenatal treatment effect, F (1,19) = 0.01669, p = 0.8986, Drug effect, F (1,19) = 0.8, p = 0.3823, Interaction effect, F (1,19) = 6.121, p = 0.0230, PTN: Prenatal treatment effect, F (1,19) = 10.31, p = 0.0046, Drug effect, F (1,19) = 52.02, p < 0.0001, Interaction effect, F (1,19) = 0.002927 p = 0.9574, WNT5A: Prenatal treatment effect, F (1,19) = 5.581, p = 0.0290, Drug effect, F (1,19) = 1.550, p = 0.2282, Interaction effect, F (1,19) = 0.0834 p = 0.7799, * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 as determined by 2-way ANOVA (alpha = 0.05) with Tukey’s post-hoc. # p < 0.05 for main effect of MIA. Graphs indicate mean ± s.e.m.

Article Snippet: For the detection of NCAM2, CTNND2 and WNT5A, custom ELISA kits were developed according to the manufacturer’s instruction using anti-NCAM2 goat polyclonal antibody (0.3 μg/well Acris Antibodies GmbH, AP32136PU-N), biotinylated anti-NCAM2 goat polyclonal antibody using Antibody Biotinylation Kit (0.3 μg/ml, Pierce/Thermo Scientific, 90407), anti-CTNND2 mouse monoclonal antibody (0.3 μg/well, Santa Cruz Biotechnology, SC-81793, clone 40.1), biotinylated anti-CTNND2 rabbit antibody (1 μg/ml, Abcam, EPR17628), anti-WNT5A goat polyclonal antibody (0.3 μg/well, R&D Systems, AF645), and biotinylated anti-WNT5A antibody using Antibody Biotinylation Kit (1 μg/ml, Pierce).

Techniques: Expressing, RNA Sequencing Assay, Activation Assay, In Situ Hybridization, Immunofluorescence, Labeling, Enzyme-linked Immunosorbent Assay, Isolation